FAM22B Inhibitors
FAM22B inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of FAM22B, a protein encoded by the FAM22B gene. These inhibitors work by engaging in a variety of molecular interactions that lead to the suppression of FAM22B's activity within cellular processes. The chemical nature of these inhibitors varies, with each possessing a unique structure that enables them to interfere with the protein's function. The mode of action of these inhibitors can be direct, such as by binding to the active site of FAM22B, thereby preventing its interaction with substrates or other proteins necessary for its function. Alternatively, the action can be indirect, affecting the protein's function through modulation of signaling pathways or cellular processes that FAM22B is involved in. These inhibitors are the result of targeted medicinal chemistry efforts that aim to manipulate specific biochemical pathways where FAM22B plays a pivotal role. The design of these inhibitors takes into account the structural and functional nuances of FAM22B, ensuring high specificity and efficacy in inhibiting its action.
The development of FAM22B inhibitors is grounded in the detailed understanding of FAM22B's role in cellular pathways. By focusing on the inhibition of the protein's activity, these compounds effectively downregulate the biological processes that FAM22B influences. For instance, if FAM22B is involved in the regulation of gene expression, inhibitors may prevent it from binding to DNA or interacting with transcription factors, thereby altering the expression of genes under its control. If the protein is part of a signaling cascade, the inhibitors may block the transmission of molecular signals that FAM22B facilitates. This blockade could occur through the prevention of post-translational modifications of FAM22B, which are necessary for its activity. The precise nature of the interaction between FAM22B inhibitors and their target is characterized by a high degree of specificity; the compounds are designed to minimize off-target effects and maximize the inhibition of FAM22B-related pathways. Through these mechanisms, FAM22B inhibitors achieve a reduction in the functional activity of FAM22B, subsequently influencing the cellular functions it regulates.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib targets the EGFR tyrosine kinase domain, which is downstream of FAM22B in the signaling cascade. By inhibiting EGFR, Gefitinib indirectly decreases the activation of downstream signaling pathways where FAM22B may play a role, leading to reduced functional activity of FAM22B. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and together the complex inhibits mTOR, which is a key regulator of cell growth and proliferation. Since FAM22B is involved in cell cycle regulation, inhibiting mTOR would lead to a reduction in FAM22B activity as part of the cell cycle control mechanism. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of the PI3k/Akt pathway. As FAM22B might be regulated by PI3k/Akt signaling due to its involvement in cell survival and growth, inhibition of this pathway by LY294002 would result in decreased activity of FAM22B. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDAC). By altering the acetylation status of histones, Trichostatin A can change the expression profile of genes, potentially including those that regulate FAM22B activity or stability, leading to its decreased function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor and since FAM22B is potentially involved in cell cycle progression, inhibiting CDK4/6 would result in cell cycle arrest at the G1 phase, which in turn would decrease the activity of FAM22B involved in this process. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the 26S proteasome, leading to the accumulation of proteins destined for degradation. If FAM22B is subjected to proteasomal degradation, bortezomib may indirectly affect its function by altering the turnover of proteins regulating FAM22B activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several receptor tyrosine kinases, including VEGFR and PDGFR. As these kinases may indirectly regulate FAM22B activity through angiogenesis and cell proliferation pathways, Sorafenib can lead to reduced FAM22B activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits Bcr-Abl and c-Kit, which are involved in different signaling pathways that may intersect with FAM22B function. By inhibiting these kinases, Imatinib could reduce the signaling that contributes to FAM22B activity. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide modulates the expression of multiple signaling molecules. If any of these are upstream regulators of FAM22B, the functional activity of FAM22B could be indirectly reduced by altering the signaling environment it operates within. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an mTOR kinase inhibitor distinct from rapamycin. By inhibiting both mTORC1 and mTORC2 complexes, it could disrupt processes that regulate the activity or stability of FAM22B, leading to a decrease in FAM22B function. | ||||||